Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jun 10, 2026, 5:02 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 36 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Angiotensin Receptor Antagonists Clear all
Completed Phase 4 Interventional Results available

The Effects of Moderate vs. Aggressive Treatment With Valsartan + Amlodipine on Patients With Hypertension Uncontrolled by Angiotensin-Receptor Blocker (Herein, ARB) Monotherapy

NCT00666536
View directory record Official record
Conditions
Hypertension
Interventions
valsartan and amlodipine
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years and older
Enrollment
728 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
1
States / cities
Metairie, Louisiana
Source: ClinicalTrials.gov public record
Updated Oct 26, 2016 · Synced Jun 10, 2026, 5:02 AM EDT
Completed No phase listed Observational

A Retrospective Analysis of the Use of ACE-inhibitors and Angiotensin Receptor Blockers

NCT00321945
View directory record Official record
Conditions
Atrial Fibrillation, Atrial Flutter
Interventions
ACE-Inhibitors and Angiotensin Receptor Blockers
Procedure
Lead sponsor
Emory University
Other
Eligibility
18 Years to 65 Years
Enrollment
546 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
3
States / cities
Atlanta, Georgia • Decatur, Georgia
Source: ClinicalTrials.gov public record
Updated Sep 26, 2013 · Synced Jun 10, 2026, 5:02 AM EDT
Completed Phase 3 Interventional

The Role of Angiotensin Type I Receptor in the Regulation of Human Coronary Vascular Function

NCT00001629
View directory record Official record
Conditions
Atherosclerosis, Heart Failure, Congestive, Hypertension, Myocardial Infarction
Interventions
Angiotensin II type 1 receptor antagonists
Drug
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
Not listed
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2000
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Jun 10, 2026, 5:02 AM EDT
Withdrawn Phase 3 Interventional

Optimal Treatment for Kidney Disease in HIV Infected Adults

NCT00089518
View directory record Official record
Conditions
HIV Infections, Kidney Disease
Interventions
Valsartan
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
10
States / cities
Indianapolis, Indiana • St Louis, Missouri • New York, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 8, 2015 · Synced Jun 10, 2026, 5:02 AM EDT
Recruiting Phase 3 Interventional

A Study to Learn More About How Well the Study Treatment Finerenone Works, How Safe it is, How it Moves Into, Through, and Out of the Body, and the Effects it Has on the Body When Taken With an ACE Inhibitor or Angiotensin Receptor Blocker in Children With Chronic Kidney Disease and Proteinuria

NCT05196035
View directory record Official record
Conditions
Chronic Kidney Disease, Proteinuria
Interventions
Finerenone (Kerendia, BAY94-8862), Placebo
Drug
Lead sponsor
Bayer
Industry
Eligibility
6 Months to 17 Years
Enrollment
219 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
19
States / cities
Phoenix, Arizona • Los Angeles, California • Palo Alto, California + 16 more
Source: ClinicalTrials.gov public record
Updated Apr 16, 2026 · Synced Jun 10, 2026, 5:02 AM EDT
Completed Not applicable Interventional Results available

A Controlled Trial of Losartan in Posttraumatic Stress Disorder

NCT02709018
View directory record Official record
Conditions
Posttraumatic Stress Disorder
Interventions
losartan, Placebo
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years to 70 Years
Enrollment
149 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
6
States / cities
La Jolla, California • Washington D.C., District of Columbia • Bethesda, Maryland + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 11, 2021 · Synced Jun 10, 2026, 5:02 AM EDT
Completed Phase 4 Interventional Results available

Do Angiotensin Receptor Blockers Mitigate Progression to Acute Respiratory Distress Syndrome With SARS-CoV-2 Infection

NCT04340557
View directory record Official record
Conditions
SARS-CoV Infection
Interventions
Losartan
Drug
Lead sponsor
Sharp HealthCare
Other
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
3
States / cities
La Mesa, California • San Diego, California
Source: ClinicalTrials.gov public record
Updated May 25, 2021 · Synced Jun 10, 2026, 5:02 AM EDT
Completed Phase 2 Interventional Results available

The Antihypertensives and Vascular, Endothelial and Cognitive Function Trial

NCT00605072
View directory record Official record
Conditions
Cognitive Impairment, Hypertension, Aging
Interventions
candesartan, lisinopril, hydrochlorothiazide, nifedipine, long acting, metoprolol, long-acting
Drug
Lead sponsor
University of Southern California
Other
Eligibility
60 Years and older
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
2
States / cities
Los Angeles, California • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 14, 2013 · Synced Jun 10, 2026, 5:02 AM EDT
Completed Phase 4 Interventional

Treatment of High Blood Pressure Using Olmesartan With Hydrochlorothiazide Compared to an ACE Inhibitor With a Calcium Channel Blocker

NCT00185120
View directory record Official record
Conditions
Hypertension
Interventions
Olmesartan medoxomil, Hydroclorothiazide, Benazepril, Amlodipine
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years and older
Enrollment
152 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
20
States / cities
Mobile, Alabama • Long Beach, California • Los Angeles, California + 17 more
Source: ClinicalTrials.gov public record
Updated Jan 17, 2012 · Synced Jun 10, 2026, 5:02 AM EDT
Completed Phase 3 Interventional Results available

Blood Pressure Lowering Ability and Safety of an Olmesartan and Amlodipine Based Treatment Regimen in Patients With Stage I and Stage II Hypertension

NCT00527514
View directory record Official record
Conditions
Hypertension
Interventions
Amlodipine, Olmesartan medoxomil plus amlodipine
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years and older
Enrollment
185 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
18
States / cities
Buena Park, California • Long Beach, California • Los Angeles, California + 15 more
Source: ClinicalTrials.gov public record
Updated Nov 10, 2009 · Synced Jun 10, 2026, 5:02 AM EDT
Completed Phase 2 Interventional Results available

Randomized, Double-Blind, Safety and Efficacy Study of RE-021 (Sparsentan) in Focal Segmental Glomerulosclerosis

NCT01613118
View directory record Official record
Conditions
Focal Segmental Glomerulosclerosis
Interventions
RE-021 (Sparsentan), Irbesartan
Drug
Lead sponsor
Travere Therapeutics, Inc.
Industry
Eligibility
8 Years to 75 Years
Enrollment
109 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2024
U.S. locations
28
States / cities
San Diego, California • Torrance, California • Denver, Colorado + 19 more
Source: ClinicalTrials.gov public record
Updated May 14, 2025 · Synced Jun 10, 2026, 5:02 AM EDT
Completed Phase 4 Interventional Results available

An Examination of the Blood Pressure Lowering Ability and Safety of Olmesartan Medoxomil in Patients With Type II Diabetes

NCT00403481
View directory record Official record
Conditions
Hypertension
Interventions
olmesartan medoxomil, Olmesartan medoxomil plus Hydrochlorothiazide
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years and older
Enrollment
192 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
27
States / cities
Birmingham, Alabama • Mesa, Arizona • Searcy, Arkansas + 24 more
Source: ClinicalTrials.gov public record
Updated Nov 2, 2016 · Synced Jun 10, 2026, 5:02 AM EDT
Not yet recruiting Not applicable Interventional

RAndomized EHR-based Prescribing to Improve Disease-modifying Therapies for Cardio-Kidney-Metabolic Care (RAPID-CKM)

NCT07605390
View directory record Official record
Conditions
Chronic Kidney Disease, Type 2 Diabetes
Interventions
Epic-Based Clinician Notification, Usual Care
Other
Lead sponsor
Baylor Research Institute
Other
Eligibility
18 Years and older
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
2
States / cities
Dallas, Texas • Plano, Texas
Source: ClinicalTrials.gov public record
Updated May 25, 2026 · Synced Jun 10, 2026, 5:02 AM EDT
Completed Phase 3 Interventional Results available

Study of Sparsentan in Patients With Primary Focal Segmental Glomerulosclerosis (FSGS)

NCT03493685
View directory record Official record
Conditions
Focal Segmental Glomerulosclerosis
Interventions
sparsentan, Irbesartan
Drug
Lead sponsor
Travere Therapeutics, Inc.
Industry
Eligibility
8 Years to 75 Years
Enrollment
371 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
87
States / cities
Mesa, Arizona • Phoenix, Arizona • Los Angeles, California + 73 more
Source: ClinicalTrials.gov public record
Updated Apr 16, 2026 · Synced Jun 10, 2026, 5:02 AM EDT
Terminated Not applicable Interventional Results available

Angiotensin Receptors and Age Related Mitochondrial Decline in HIV Patients

NCT02606279
View directory record Official record
Conditions
HIV, Aging, Sarcopenia, Angiotensin Receptor Antagonists
Interventions
valsartan, Placebo
Drug · Other
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
40 Years to 60 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 27, 2018 · Synced Jun 10, 2026, 5:02 AM EDT
Withdrawn Phase 4 Interventional

Ertugliflozin Versus Hydrochlorothiazide in Reducing Sympathetic Neural Overactivity in Patients With Hypertension and Recently-diagnosed Type 2 Diabetes.

NCT03640221
View directory record Official record
Conditions
Hypertension, Diabetes Mellitus, Type 2
Interventions
Ertugliflozin, Hydrochlorothiazide 12.5mg, Microneurography, SKNA recordings, Static Handgrip, Post-handgrip forearm vascular occlusion, Testing of the Arterial Baroreflex Function
Drug · Device · Other
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
35 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jan 13, 2020 · Synced Jun 10, 2026, 5:02 AM EDT
Completed Phase 1 Interventional

An ACE Inhibitor (Perindopril) or an Angiotensin Receptor Blocker (Candesartan) as a Treatment for Methamphetamine Dependence

NCT01062451
View directory record Official record
Conditions
Methamphetamine Dependence, Methamphetamine Abuse, Substance Abuse
Interventions
Perindopril, Placebo, Candesartan
Drug
Lead sponsor
Baylor College of Medicine
Other
Eligibility
18 Years to 55 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 25, 2022 · Synced Jun 10, 2026, 5:02 AM EDT
Completed Phase 4 Interventional Results available

Angiotensin II in General Anesthesia

NCT03733145
View directory record Official record
Conditions
Hypertension
Interventions
Angiotensin II
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
40 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 23, 2025 · Synced Jun 10, 2026, 5:02 AM EDT
Terminated Phase 4 Interventional Results available

Pulmonary Artery Pressure Reduction With ENTresto (Sacubitril/Valsartan)

NCT02788656
View directory record Official record
Conditions
Congestive Heart Failure
Interventions
Implantable Hemodynamic Monitor, Angiotensin-Converting Enzyme Inhibitor, Angiotensin II Type 1 Receptor Blocker, sacubitril/valsartan
Device · Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 16, 2020 · Synced Jun 10, 2026, 5:02 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

The Role of Angiotensin Type I Receptor in the Regulation of Human Peripheral Vascular Function

NCT00001628
View directory record Official record
Conditions
Atherosclerosis, Heart Failure, Congestive, Hypertension, Myocardial Infarction
Interventions
Angiotensin II type 1 receptor antagonists
Drug
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
Not listed
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1997 – 2000
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Jun 10, 2026, 5:02 AM EDT
Completed Phase 2 Interventional

Evaluate the Efficacy and Safety of Once Daily Administration of Atrasentan Tablets (Low and High) Compared to Placebo in Reducing Residual Albuminuria in Type 2 Diabetic Patients With Nephropathy Who Are Treated With the Maximum Tolerated Labeled Dose of a Renin Angiotensin System (RAS) Inhibitor

NCT01356849
View directory record Official record
Conditions
Chronic Kidney Disease, Diabetic Nephropathy
Interventions
Atrasentan, Placebo
Drug
Lead sponsor
AbbVie (prior sponsor, Abbott)
Industry
Eligibility
18 Years and older
Enrollment
149 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
59
States / cities
Pell City, Alabama • Tempe, Arizona • Azusa, California + 48 more
Source: ClinicalTrials.gov public record
Updated Aug 27, 2013 · Synced Jun 10, 2026, 5:02 AM EDT
Completed No phase listed Observational

ACEI or ARB and COVID-19 Severity and Mortality in US Veterans

NCT04467931
View directory record Official record
Conditions
Hypertension, COVID
Interventions
ACEI/ARB, Non-ACEI/ARB, ACEI, ARB
Drug
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older
Enrollment
22,213 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Apr 27, 2021 · Synced Jun 10, 2026, 5:02 AM EDT
Completed Not applicable Interventional Results available

Elimination or Prolongation of ACE Inhibitors and ARB in Coronavirus Disease 2019

NCT04338009
View directory record Official record
Conditions
COVID-19
Interventions
Discontinuation of ARB/ACEI, Continuation of ARB/ACEI
Other
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
152 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 8, 2021 · Synced Jun 10, 2026, 5:02 AM EDT
Completed Phase 4 Interventional Results available

Efficacy of Losartan in Preventing Progression of COPD

NCT00720226
View directory record Official record
Conditions
COPD, Emphysema, Chronic Bronchitis, Smoking
Interventions
Losartan, Placebo
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
40 Years and older
Enrollment
106 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2016
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 24, 2017 · Synced Jun 10, 2026, 5:02 AM EDT